☢️A very good wrap-up for using SBRT in the era of immunotherapy among patients with kidney cancer! doi.org/10.1016/j.euru… Laurence Albiges Toni Choueiri, MD Rana McKay, MD, FASCO OncoAlert #kidneycancer #Cancer #CancerResearch

Interesting data on stage migration in THUNDER trial. Much higher percentage (1/3) upstaged compared to proPSMA. Higher risk population or did proPSMA understage? #ESTRO2025

Might PET based inhomogenous dose escalation be an approach to permit dose escalation in stage 3 #lungcancer /#NSCLC? ➡️With modest toxicity rates and RT dose escation to median of 88.1 Gy to GTV, The phase 3 NARLAL2 trial suggests it may be #RadOnc 🔗ascopubs.org/doi/abs/10.120…

Excited to share our recent article "Evaluating the Safety and Efficacy of Adding Liver-Directed Radiation Therapy to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma A Single-Center Retrospective Cohort Analysis" out now in AJCO journals.lww.com/amjclinicalonc…

Simon Lo Joshua D. Palmer, MD Jeff Ryckman ASCO NatureRevClinOncol But does it really half the growth? Stable disease no different from placebo, ORR 11% vs 3% placebo...Vorasidenib has no effect on 90% tumors

📊 Breaking! FLAME trial 10-yr results show focal boost to MRI-visible tumors significantly improves outcomes in intermediate/high-risk prostate cancer: • bDFS: 86% vs 71% (HR 0.40, p<0.0001) • DFS: 81% vs 66% (p<0.001) #ESTRO25 ESTRO

Comparison of toxicity w 3D v IMRT in RAPIDO: IMRT worse. Table summarizes studies of 3D v IMRT in rectal ca – w RAPIDO, data mixed. Caveat that RAPIDO didn’t require OAR delineation/ specify constraints, but good reminder that advanced tech doesn’t guarantee better outcomes.

I rarely praise Trump but this is a genuinely incredible speech I've been arguing for close to a decade that the single biggest reason for the growing divide between the West and "the rest" was the West's inability to accept diversity (the genuine kind,

Excited to share our recent nature paper! nature.com/articles/s4158… Tremendous collaborative effort from UChicagoCancerCenter The University of Chicago University of Chicago Radiation Oncology Ralph Weichselbaum

Last week, I was a guest speaker at International Democracy Union, a platform of center-right political forces founded in the 1980s by figures like Ronald Reagan, Margaret Thatcher, and Helmut Kohl. Here’s my full speech on why conservatives are the true heirs of the Enlightenment, defending

Am I the only one questioning the “unbridled enthusiasm” for cCRT that is based the phase III RTOG 9410 study conducted 30y ago? Can we please revisit sCRT with the vigor it deserves to optimize RT safety and efficacy? Does anyone even use bolus vinblastine q5w anymore? #ASCO25

Matt Spraker Ours is this one!! Reena Engineer ascopubs.org/doi/10.1200/JC…

🧵1/ Big news in unresectable stage III NSCLC. The InTRist study is the first randomized trial comparing NAC vs. neoadjuvant chemoimmunotherapy (NAC-ICI) prior to definitive chemoradiotherapy (CRT). Early results are promising. Let’s dig in. 🔍 #LungCancer #RadOnc #ASCO25

Lots of this regulation is caused by the LNT model (linear non-threshold model), which assumes that any bit of radiation is bad—stupid when the background has plenty of radiation. We can eliminate that.

The highlight of #ASCO25 was the AMPLITUDE trial presented by AttardLab on PARPi in HRR altered mHSPC. Listen to our podcast discussing these practice-changing data! spotifycreators-web.app.link/e/77hbNX73YTb

If you’re curious what Shankar Siva is up to next, say hello to the recently funded phase III randomized PRIME-LUNG study (n=420). #SABRCAN25

When I started oncology training there was a very minimal place for radiotherapy in the treatment of #ovariancancer Systematic review just out in ESTRO European ctRO journal suggests #SABR ⬆️ PFS and OS in ovarian ca and is synergistic with PARPi sciencedirect.com/science/articl…

☢️Pancreatic SBRT and toxicity Journal of the @NCCN ➡️2 decades, 507 patients 🚨Early (90days) toxicity: Infection ❗️Severe GI toxicity: late ( median 10.9 mo) ➡️ dose related 👉jnccn.org/view/journals/… #cancer #oncology #pancreatic #MedX OncoAlert M. Bolton Dr. Nina Niu Sanford Jeff Ryckman

Excited to share our experience (largest so far) using Boswellia for radiation necrosis with brain mets. ORR 60%, median duration 14 months. Amazing responses and a game changer for patients, I highly recommend you check it out!!! pubmed.ncbi.nlm.nih.gov/39993542/ redjournal.org/article/S0360-…

The Gleason score - the fundamental determinant of how we chose on treatments in localized prostate cancers - basically doesn't make any sense.